-
Something wrong with this record ?
Immunobiological effects of lipopolysaccharide derived from Helicobacter pylori and influence of a proton pump inhibitor lansoprazole on human polymorphonuclear leukocytes
Y. Koshibu, T. Ubagai, Y. Yoshino, Y. Ono
Language English Country Czech Republic
Document type Journal Article
- MeSH
- Cytokines metabolism genetics MeSH
- Escherichia coli drug effects genetics MeSH
- Helicobacter pylori * drug effects genetics MeSH
- Proton Pump Inhibitors * pharmacology chemistry MeSH
- Lansoprazole * pharmacology chemistry MeSH
- Humans MeSH
- Lipopolysaccharides * metabolism pharmacology MeSH
- Neutrophils * drug effects immunology MeSH
- Reactive Oxygen Species metabolism MeSH
- Toll-Like Receptor 4 metabolism genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Helicobacter pylori colonizes the human gastric mucosa of more than half of the human population and has a unique lipopolysaccharide (LPS) structure. LPS is the most dominant and suitable pathogen-associated molecular pattern that is detected via pattern recognition receptors. Although the priming effect of H. pylori LPS on reactive oxygen species (ROS) production of PMNs is lower than that of Escherichia coli O111:B4 LPS, LPS released from H. pylori associated with antibiotics eradication therapy may activate PMNs and increase ROS production. In addition, we describe the effects of H. pylori and E. coli O111:B4 LPSs on gene expression and the anti-inflammatory effect of lansoprazole (LPZ) in human polymorphonuclear leukocytes. LPS isolated from H. pylori and E. coli O111:B4 alters toll-like receptor 2 (TLR) and TLR4 expressions similarly. However, LPS from E. coli O111:B4 and H. pylori caused a 1.8-fold and 1.5-fold increase, respectively, in CD14 expression. All LPS subtypes upregulated TNFα and IL6 expression in a concentration-dependent manner. Although E. coli O111:B4 LPS upregulated IL8R mRNA levels, H. pylori LPS did not (≦ 100 ng/mL). Gene expression levels of ITGAM demonstrated no significant change on using both LPSs. These different effects on the gene expression in PMNs may depend on variations in LPS structural modifications related to the acquired immunomodulatory properties of H. pylori LPS. Proton pump inhibitors, i.e., LPZ, are used in combination with antibiotics for the eradication therapy of H. pylori. LPZ and its acid-activated sulphenamide form AG-2000 suppress ROS production of PMNs in a dose-dependent manner. These results suggest that LPZ combination with antibiotics for H. pylori eradication reduces gastric inflammation by suppressing ROS release from PMNs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24020969
- 003
- CZ-PrNML
- 005
- 20241105105520.0
- 007
- ta
- 008
- 241105s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-024-01188-7 $2 doi
- 035 __
- $a (PubMed)39153156
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Koshibu, Yoji $u Department of Microbiology & Immunology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan
- 245 10
- $a Immunobiological effects of lipopolysaccharide derived from Helicobacter pylori and influence of a proton pump inhibitor lansoprazole on human polymorphonuclear leukocytes / $c Y. Koshibu, T. Ubagai, Y. Yoshino, Y. Ono
- 520 9_
- $a Helicobacter pylori colonizes the human gastric mucosa of more than half of the human population and has a unique lipopolysaccharide (LPS) structure. LPS is the most dominant and suitable pathogen-associated molecular pattern that is detected via pattern recognition receptors. Although the priming effect of H. pylori LPS on reactive oxygen species (ROS) production of PMNs is lower than that of Escherichia coli O111:B4 LPS, LPS released from H. pylori associated with antibiotics eradication therapy may activate PMNs and increase ROS production. In addition, we describe the effects of H. pylori and E. coli O111:B4 LPSs on gene expression and the anti-inflammatory effect of lansoprazole (LPZ) in human polymorphonuclear leukocytes. LPS isolated from H. pylori and E. coli O111:B4 alters toll-like receptor 2 (TLR) and TLR4 expressions similarly. However, LPS from E. coli O111:B4 and H. pylori caused a 1.8-fold and 1.5-fold increase, respectively, in CD14 expression. All LPS subtypes upregulated TNFα and IL6 expression in a concentration-dependent manner. Although E. coli O111:B4 LPS upregulated IL8R mRNA levels, H. pylori LPS did not (≦ 100 ng/mL). Gene expression levels of ITGAM demonstrated no significant change on using both LPSs. These different effects on the gene expression in PMNs may depend on variations in LPS structural modifications related to the acquired immunomodulatory properties of H. pylori LPS. Proton pump inhibitors, i.e., LPZ, are used in combination with antibiotics for the eradication therapy of H. pylori. LPZ and its acid-activated sulphenamide form AG-2000 suppress ROS production of PMNs in a dose-dependent manner. These results suggest that LPZ combination with antibiotics for H. pylori eradication reduces gastric inflammation by suppressing ROS release from PMNs.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a lipopolysacharidy $x metabolismus $x farmakologie $7 D008070
- 650 12
- $a Helicobacter pylori $x účinky léků $x genetika $7 D016480
- 650 12
- $a lanzoprazol $x farmakologie $x chemie $7 D064747
- 650 12
- $a inhibitory protonové pumpy $x farmakologie $x chemie $7 D054328
- 650 12
- $a neutrofily $x účinky léků $x imunologie $7 D009504
- 650 _2
- $a Escherichia coli $x účinky léků $x genetika $7 D004926
- 650 _2
- $a toll-like receptor 4 $x metabolismus $x genetika $7 D051197
- 650 _2
- $a reaktivní formy kyslíku $x metabolismus $7 D017382
- 650 _2
- $a cytokiny $x metabolismus $x genetika $7 D016207
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ubagai, Tsuneyuki $u Department of Microbiology & Immunology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan. ubat@med.teikyo-u.ac.jp $1 https://orcid.org/0000000287105918
- 700 1_
- $a Yoshino, Yusuke $u Department of Microbiology & Immunology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan
- 700 1_
- $a Ono, Yasuo $u Department of Microbiology & Immunology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-Ku, Tokyo, 173-8605, Japan $u Faculty of Health and Medical Science, Teikyo Heisei University, Tokyo, 170-8445, Japan
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 69, č. 6 (2024), s. 1369-1378
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39153156 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241105 $b ABA008
- 991 __
- $a 20241105105516 $b ABA008
- 999 __
- $a ok $b bmc $g 2209286 $s 1232959
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 69 $c 6 $d 1369-1378 $e 20240817 $i 1874-9356 $m Folia microbiologica $n Folia Microbiol (Praha) $x MED00011005
- LZP __
- $a Pubmed-20241105
